Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year.
The week witnessed a few COVID-19 disappointments. CureVac N.V. CVAC confirmed the sub-par efficacy data for its first-generation vaccine against the novel coronavirus.
Altimmune, Inc. ALT shares fell about 43% for the week after it announced it is rolling up its intranasal COVID-19 vaccine program. The company was also forced to stop enrollment into the phase 1/2 trial for T-COVID, its single dose intranasal therapeutic for treating early COVID-19. Angion Biomedica Corp. ANGN decided to shelve its COVID-19 program following a failed Phase 2 study.
Several R&D collaborations and licensing deals were announced during the week. Alector, Inc. ALEC shares jumped Friday after it announced an out-licensing deal with GlaxoSmithKline plc GSK for two monoclonal antibodies being evaluated for the treatment of neurodegenerative diseases.
Among the stocks that made their Wall Street debuts were Acumen Pharmaceuticals, Inc. ABOS, medical device maker CVRx, Inc. CVRX and Aerovate Therapeutics, Inc. (AVTE), a cardiopulmonary diseases focused biopharma. POINT Biopharma Inc. PNT made its debut through a SPAC deal.
Here are the key catalytic events for the unfolding week.
- European Crohn's and Colitis Organization, or ECCO, 16th Annual Congress: July 2-3 & July 8-10
- Society for Reproductive Investigation, SRI, 68th Annual Meeting: July 6-9
- European Academy of Allergy and Clinical Immunology, or EAACI, Annual Congress 2021, to be held virtually: July 10-16
Related Link: 14 Biotech Stocks To Watch Over The Next 6 Months
The FDA is scheduled to rule on ChemoCentryx, Inc.'s CCXI new drug application for avacopan, an orally-administered small molecule being evaluated for the treatment of ANCA-associated vasculitis and other complement-driven autoimmune and inflammatory diseases. An FDA panel that reviewed the NDA in early May issued a split verdict.
ObsEva SA OBSV is due to present at the SRI annual meeting results from the proof-of-concept trial of ebopiprant for the treatment of spontaneous preterm labor. The oral presentation is scheduled for Wednesday, July 7, at 4-5:30 pm
Morphic Holding, Inc. MORF will host a webcast and conference call at 8 am on Friday, July 9 to discuss results from the phase 1 study of MORF-057 in inflammatory bowel disease. The company will also present the data at the ECCO Congress.
Pharvaris N.V. PHVS will present clinical data for oral PHA121 that is being evaluated for the treatment of hereditary angioedema, as an e-Poster at the EAACI annual congress. The abstract will be published on the EAACI website on Saturday, July 10. The virtual poster presentation will be on the EAACI website from July 10-16.
IPO Quiet Period Expiry
Janux Therapeutics, Inc. JANX
Alzamend Neuro, Inc. ALZN
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.